# Progress Note 04 — Sick Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Flannery O'Connor (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML046-SYN
- Date: 2026-06-15
- Fictional facility: St. Posthumous Health Center
- Fictional author: Augusta Pemberton-Diallo, MD
- Calendar frame: modern shifted

- Visit type: Sick Visit
- Services: Problem-oriented office visit, established patient

## Chief complaint

Burning on passing urine and going often for two days. **S**

## History of present illness

Ms. O'Connor is a 25-year-old writer with systemic lupus erythematosus and class III lupus nephritis, seven weeks into treatment with mycophenolate 1000 mg twice daily, weekly belimumab, hydroxychloroquine, losartan, and prednisone, now 15 mg a day. For two days she has had burning on passing urine, frequency, urgency, and lower abdominal discomfort. She has no fever on her home thermometer, chills, back or flank pain, vomiting, vaginal discharge, or rash, and her joints are quiet. She has a levonorgestrel intrauterine system. She called because she had been told that any infection on her treatment should be seen the same day, and she wanted to know whether this was her kidneys. **S**

| Element | Detail |
|---|---|
| Onset | Two days ago |
| Location | Bladder; no flank pain |
| Duration | Two days |
| Character | Burning, frequency, urgency |
| Severity | Moderate; writing still |
| Context | Mycophenolate, belimumab, and prednisone 15 mg; intrauterine system |
| Modifying factors | Extra fluids help a little |
| Associated signs and symptoms | No fever, chills, flank pain, vomiting, or discharge |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or chills |
| Genitourinary | Positive | Dysuria, frequency, urgency, suprapubic discomfort; no flank pain or discharge |
| Gastrointestinal | Negative | No vomiting or diarrhea |
| Musculoskeletal | Negative | No joint pain or swelling |
| Integumentary | Negative | No rash |

5 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for joint pain, no more than 3000 mg a day **S**
- Hydroxychloroquine sulfate 300 mg oral tablet, one tablet by mouth once daily (5 mg/kg of actual body weight), long term **S**
- Losartan potassium 25 mg oral tablet, one tablet by mouth once daily, for proteinuria and blood pressure **S**
- Prednisone 5 mg oral tablet: 30 mg (six tablets) once daily from the day after the last pulse, reduced by 5 mg every two weeks to 10 mg, then to 5 mg a day or less by six months **S**
- Mycophenolate mofetil 500 mg oral tablet, one tablet twice daily for one week, then two tablets (1000 mg) twice daily **S**
- Belimumab 200 mg/mL subcutaneous autoinjector: 400 mg (two injections) once weekly for four doses, then 200 mg once weekly **S**
- Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily **S**
- Nitrofurantoin (monohydrate/macrocrystals) 100 mg oral capsule, one capsule by mouth twice daily with food for seven days **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/78 mmHg; pulse 84 bpm; respirations 14/min; temperature 37.3 °C; oxygen saturation 99% on room air; weight 62.4 kg; BMI 22.1 kg/m². All vital signs are synthetic.

White cell count: 7.9 10*3/uL; Creatinine: 0.8 mg/dL; Potassium: 4.6 mmol/L. All results are synthetic.

## Change since baseline

- White cell count: 3.3 10*3/uL (low) at baseline, 7.9 10*3/uL at this visit **S**
- Creatinine: 0.8 mg/dL at baseline, 0.8 mg/dL at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 4.6 mmol/L at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well-appearing; temperature 37.3 °C, pulse 84/min |
| Abdomen | Mild suprapubic tenderness; no masses |
| Back | No costovertebral angle tenderness |
| Skin | No malar rash; no lesions |
| Musculoskeletal | No joint swelling or tenderness |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Acute cystitis in an immunosuppressed woman** (N30.00). Typical bladder symptoms with leukocyte esterase and nitrite on the dipstick, no fever, and no flank tenderness: cystitis without signs of kidney infection. Prednisone can hide fever, so the threshold to treat and to culture is low. White cell count 7.9, creatinine 0.8 unchanged. Nitrofurantoin is first-line with her normal kidney function; trimethoprim-sulfamethoxazole is avoided because sulfonamides can provoke lupus flares and drug reactions. **S**
   - Urine culture sent before the first dose.
   - Nitrofurantoin 100 mg twice daily with food for seven days, a longer course because she is immunosuppressed.
   - Same-day call for fever, chills, flank pain, or vomiting, which would need assessment for kidney infection.
   - Urine protein-to-creatinine ratio and sediment not measured today, since infection distorts both; they will be repeated at the three-month visit after the infection clears.
2. **Lupus nephritis on treatment** (M32.14). No sign of a flare: joints quiet, no rash, creatinine stable. Potassium 4.6, normal, is the first potassium since losartan was started. **S**
   - Continue mycophenolate, belimumab, hydroxychloroquine, losartan, and the prednisone taper without change.
   - Basic metabolic panel added to the standing blood count orders.

## Medication changes

- Started: Nitrofurantoin (monohydrate/macrocrystals) 100 mg oral capsule, one capsule by mouth twice daily with food for seven days **S**

## Guideline basis

- EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83(1):15-29 (2023), EULAR
- 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol 2025;77(9):1115-1135 (2024), American College of Rheumatology
- International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the IDSA and ESCMID. Clin Infect Dis 2011;52(5):e103-e120 (2010), Infectious Diseases Society of America

## Follow-up

- Culture result by telephone in two days. Rheumatology blood count as scheduled. Three-month review in six weeks. **S**
- Next scheduled visit 2026-07-27: three-month response assessment for lupus nephritis and glucocorticoid taper. **S**
